Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Spratt

Showing results (541-550 of 666) with videos related to

Pageof 67
Sort By:
International Journal of Radiation Oncology, Biology, Physics|July 6, 2019
Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation TherapyNaomi Y Jiang, Audrey T Dang, Ye Yuan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2020
Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With RadiationWanling Xie, Meredith M Regan, Marc Buyse, et al.
International Journal of Radiation Oncology, Biology, Physics|October 2, 2024
Setting the Stage: Feasibility and Baseline Characteristics in the PARTIQoL Trial Comparing Proton Therapy Versus Intensity Modulated Radiation Therapy for Localized Prostate CancerAmy J Wisdom, Beow Y Yeap, Jeff M Michalski, et al.
International Journal of Radiation Oncology, Biology, Physics|July 25, 2022
A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for Locally Advanced Prostate CancerLiat Hammer, Ralph Jiang, Jason Hearn, et al.
JCO Precision Oncology|June 6, 2025
Cross-Comparison Individual Patient-Level Analysis of Three Gene Expression Signatures in Localized Prostate in Over 50,000 MenAngela Y Jia, Yilun Sun, Maitry Patel, et al.
The Lancet. Oncology|October 17, 2016
Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysisShuang G Zhao, S Laura Chang, Daniel E Spratt, et al.
International Journal of Radiation Oncology, Biology, Physics|July 25, 2025
Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115)Daniel A Hamstra, James J Dignam, Deborah W Bruner, et al.
JCO Precision Oncology|October 24, 2024
Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multimodal Deep Learning With Digital HistopathologyJonathan David Tward, Huei-Chung Huang, Andre Esteva, et al.
Journal of the National Cancer Institute|October 16, 2018
The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic TargetShuang G Zhao, Jonathan Lehrer, S Laura Chang, et al.
International Journal of Radiation Oncology, Biology, Physics|September 25, 2024
Erratum to: Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2023;117:370-377Daniel E Spratt, Vinnie Y T Liu, Jeff Michalski, et al.
Pageof 67

Showing results (541-550 of 666) with videos related to

Sort By:
Pageof 67
International Journal of Radiation Oncology, Biology, Physics|July 6, 2019
Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation TherapyNaomi Y Jiang, Audrey T Dang, Ye Yuan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2020
Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With RadiationWanling Xie, Meredith M Regan, Marc Buyse, et al.
International Journal of Radiation Oncology, Biology, Physics|October 2, 2024
Setting the Stage: Feasibility and Baseline Characteristics in the PARTIQoL Trial Comparing Proton Therapy Versus Intensity Modulated Radiation Therapy for Localized Prostate CancerAmy J Wisdom, Beow Y Yeap, Jeff M Michalski, et al.
International Journal of Radiation Oncology, Biology, Physics|July 25, 2022
A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for Locally Advanced Prostate CancerLiat Hammer, Ralph Jiang, Jason Hearn, et al.
JCO Precision Oncology|June 6, 2025
Cross-Comparison Individual Patient-Level Analysis of Three Gene Expression Signatures in Localized Prostate in Over 50,000 MenAngela Y Jia, Yilun Sun, Maitry Patel, et al.
The Lancet. Oncology|October 17, 2016
Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysisShuang G Zhao, S Laura Chang, Daniel E Spratt, et al.
International Journal of Radiation Oncology, Biology, Physics|July 25, 2025
Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115)Daniel A Hamstra, James J Dignam, Deborah W Bruner, et al.
JCO Precision Oncology|October 24, 2024
Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multimodal Deep Learning With Digital HistopathologyJonathan David Tward, Huei-Chung Huang, Andre Esteva, et al.
Journal of the National Cancer Institute|October 16, 2018
The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic TargetShuang G Zhao, Jonathan Lehrer, S Laura Chang, et al.
International Journal of Radiation Oncology, Biology, Physics|September 25, 2024
Erratum to: Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2023;117:370-377Daniel E Spratt, Vinnie Y T Liu, Jeff Michalski, et al.
Pageof 67